Clearmind Medicine Inc. (CMND)
NASDAQ: CMND · IEX Real-Time Price · USD
+0.005 (0.42%)
At close: Apr 19, 2024, 4:00 PM
+0.005 (0.42%)
After-hours: Apr 19, 2024, 5:26 PM EDT

Company Description

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally.

It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.

The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction.

In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome.

The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021.

Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Clearmind Medicine Inc.
Clearmind Medicine logo
Country Canada
Founded 2017
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Dr. Adi Zuloff-Shani Ph.D.

Contact Details

101-1220 West 6th Avenue
Vancouver, British Columbia, Z4 V6H1A5
Canada (Federal Level)
Phone 972-54-5704749

Stock Details

Ticker Symbol CMND
Exchange NASDAQ
Fiscal Year November - October
Reporting Currency USD
CIK Code 0001892500
ISIN Number CA1850534027
SIC Code 2834

Key Executives

Name Position
Dr. Adi Zuloff-Shani Ph.D. Chief Executive Officer
Alan Mark Rootenberg B.Com., B.Comm, C.A., C.P.A. Chief Financial Officer
Prof. Mark Haden Vice President of Business Development
Gilad Babchuk Head of Strategy and Communication

Latest SEC Filings

Date Type Title
Apr 17, 2024 6-K Report of foreign issuer
Apr 10, 2024 6-K Report of foreign issuer
Apr 9, 2024 6-K Report of foreign issuer
Mar 27, 2024 20-F/A Filing
Mar 27, 2024 6-K Report of foreign issuer
Mar 22, 2024 EFFECT Notice of Effectiveness
Mar 20, 2024 POS AM Post-Effective amendments for registration statement
Mar 19, 2024 6-K Report of foreign issuer
Mar 18, 2024 20-F/A Filing
Mar 13, 2024 6-K Report of foreign issuer